The Latest Analyst Ratings For Editas Medicine
The Latest Analyst Ratings For Editas Medicine
Editas Medicine 的最新分析師評級
Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.
在過去的三個月中，有4位分析師對Editas Medicine（納斯達克股票代碼：EDIT）進行了評估，提供了從看漲到看跌的不同觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他們最近的評級，簡要介紹了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for Editas Medicine, revealing an average target of $14.0, a high estimate of $20.00, and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 27.27% from the previous average price target of $11.00.
分析師已經爲Editas Medicine設定了12個月的目標股價，顯示平均目標股價爲14.0美元，最高估計爲20.00美元，低估值爲9.00美元。當前的平均價格從之前的平均目標價11.00美元上漲了27.27％，這是一個積極的轉變。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析師評級：深度探索
An in-depth analysis of...
對分析師近...
登入免費觀看全文
登入/註冊